Adezmapimod

(Synonyms: SB 203580; RWJ 64809)
607 Cited Publications
고객리뷰

Based on 607 publication(s) in Google Scholar

Adezmapimod (SB 203580) is a selective and ATP-competitive p38 MAPK inhibitor with IC50s of 50 nM and 500 nM for SAPK2a/p38 and SAPK2b/p38β2, respectively. Adezmapimod inhibits LCK, GSK3β and PKBα with IC50s of 100-500-fold higher than that for SAPK2a/p38. Adezmapimod can inhibit p38 MAPK and lead to the inhibition of downstream HSP27 phosphorylation. Adezmapimod does not disrupt JNK activity and is an autophagy and mitophagy activator.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

  • Purity: 99.93%
  • CAS No.: 152121-47-6
  • 화학식: C21H16FN3OS
  • 분자량:377.43
  • 보관:
    Powder   -20°C, 3 years , 4°C, 2 years ; In solvent   -80°C, 2 years , -20°C, 1 year
  • Biological Activity
  • Chemical Information
  • 용액&용해도
  • 순도&문서
  • References
  • Help & FAQs
You May Still Need

Publications Citing Use of MedChemExpress (MCE) Adezmapimod

More
Customer Validation & Images
IFWBIHCRT-PCR
  • RT-PCR
  • WB
  • RT-PCR
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • IF
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • IHC
  • WB
  • WB
  • WB
  • WB
  • WB
  • IF
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
100 mg

견적 받기 해외재고보유

Please select quantity
Amount: USD 0.00